Antifolate agents: A patent review (2006 2010)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 9, 2011, Pages 1293-1308

  Wright, Dennis L ^a   Anderson, Amy C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antifolate; Antiproliferative; Dihydrofolate reductase; Thymidylate synthase

Indexed keywords

2 AMINO 4 OXO 6 ETHYLTHIENO[2,3 D]PYRIMIDINE; 2,4 DIAMINOQUINAZOLINE DERIVATIVE; CYCLOGUANIL; CYCLOPENTA[G]QUINAZOLINE; DIHYDROFOLATE REDUCTASE INHIBITOR; EPIGALLOCATECHIN; FLUOROURACIL; FOLATE RECEPTOR; FOLIC ACID ANTAGONIST; METHOTREXATE; N (4 AMINO 4 DEOXYPTEROYL)ORNITHINE DERIVATIVE; PEMETREXED; PYRIMETHAMINE; PYRIMIDINE DERIVATIVE; RALTITREXED; THIENOPYRIMIDINE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETHOPRIM; TRIMETREXATE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; COLORECTAL CANCER; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG LEGISLATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; MALARIA; MESOTHELIOMA; NONHUMAN; PATENT; PNEUMOCYSTIS PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; URINARY TRACT INFECTION; X RAY CRYSTALLOGRAPHY;

ANIMALS; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; MODELS, MOLECULAR; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 80052042411     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.587804     Document Type: Review

References (47)

1. Bertino J. Karnofsky memorial lecture: Ode to methotrexate. J Clin Oncol 1993;21:5-14
2. Liu J, Bolstad D, Smith A, et al. Structure-guided development of efficacious antifungal agents targeting candida glabrata dihydrofolate reductase. Chem Biol 2008;15:990-96
3. Liu J, Bolstad D, Smith A, et al. Probing the active site of candida glabrata dihydrofolate reductase with high resolution crystal structures and the synthesis of new inhibitors. Chem Biol Drug Des 2009;73:62-74
4. +. Biochemistry 1999;38:4303-12
5. Cody V, Pace J. Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5¢-(w- carboxyalkoxy) benzyl]-pyrido[2,3-d]pyrimidine derivatives. Acta Cryst 2011;D67:1-7
6. Cody V, Pace J, Chisum K, et al. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent trimethoprim derivatives. Proteins 2006;65:959-69
7. Lee J, Yennawar N, Gam J, et al. Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae. Biochemistry 2010;49:195-206
8. Beierlein J, Frey K, Bolstad D, et al. Synthetic and crystallographic studies of a new inhibitor series targeting bacillus anthracis dihydrofolate reductase. J Med Chem 2008;51:7532-40
9. Bennett B, Xu H, Simmerman R, et al. Crystal structure of the anthrax drug target, bacillus anthracis dihydrofolate reductase. J Med Chem 2007;50:4374-81 (Pubitemid 47378835)
10. Bourne C, Bunce R, Bourne P, et al. Crystal strucutre of Bacillus anthracis dihydrofolate reductase, with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity. Antimicrob Agents and Chem 2009;53:3065-73
11. Beierlein J, Karri N, Anderson A. Targeted mutations of bacillus anthracis dihydrofolate reductase condense complex structure-activity relationships. J Med Chem 2010;53:7327-36
12. Beierlein J, Deshmukh L, Frey K, et al. The solution structure of bacillus anthracis dihydrofolate reductase yields insight into the analysis of structure-activity relationships for novel inhibitors. Biochemistry 2009;48:4100-8
13. Heaslet H, Harris M, Fahnoe K, et al. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim. Proteins 2009;76:706-17
14. Hay S, Evans R, Levy C, et al. Are the catalytic properties of enzymes frompiezophilic organisms pressure adapted? Chem Bio Chem 2009;10:2348-53
15. Frey K, Georgiev I, Donald B, et al. Predicting resistance mutations using protein design algorithms. Proc Natl Acad Sci 2010;107:13707-12
16. Frey K, Liu J, Lombardo M, et al. Crystal structures of wild-type andmutant methicillin-resistant staphylococcus aureus dihydrofolate reductase reveal an alternative conformation of NADPH that may be linked to trimethoprim resistance. J Mol Biol 2009;387:1298-308
17. Frey K, Lombardo M, Wright D, et al. Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant staphylococcus aureus dihydrofolate reductase. J Struc Biol 2010;170:93-7
18. Oefner C, Bandera M, Haldimann A, et al. Increased hydrophobic interactions of iclaprim with staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother 2009;63:687-98
19. Oefner C, Parisi S, Schulz H, et al. Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Acta Cryst 2009;D65:751-57
20. Bourne C, Barrow E, Bunce R, et al. Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1. Antimicrob Agents and Chem 2010;54:3825-33
21. Cody V, Piraino J, Pace J, et al. Preferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the E and Z isomers of a series of 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines as ternary complexes with NADPH and human dihydrofolate reductase. Acta Cryst 2010;D66:1271-77
22. Gangjee A, Li W, Kisliuk R, et al. Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6- ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents. J Med Chem 2009;52:4892-902
23. Reynolds R, Campbell S, Fairchild R, et al. Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation. J Med Chem 2007;50:3283-89 (Pubitemid 47065977)
24. Costi M, Rinaldi M, Tondi D, et al. Phthalein derivatives as a new tool for selectivity in thymidylate synthase inhibition. J Med Chem 1999;42:2112-24 (Pubitemid 29284231)
25. Stout T, Tondi D, Rinaldi M, et al. structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry 1999;38:1607-17
26. Schormann N, Senkovich O, Walker K, et al. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function. Proteins 2008;73:889-901
27. Schormann N, Velu S, Murugesan S, et al. Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. Bioorg Med Chem 2010;18:4056-66
28. Chitnumsub P, Yuvaniyama J, Chahomchuen T, et al. Crystallization and preliminary crystallographic studies of dihydrofolate reductase-thymidylate synthase from Trypanosoma cruzi, the Chagas disease pathogen. Acta Cryst 2009;F65:1175-78
29. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003;10:357-65 (Pubitemid 36523270)
30. Dasgupta T, Chitnumsub P, Kamchonwongpaisan S, et al. Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria. ACS Chem Biol 2009;4:29-40
31. Nzila A, Rottman M, Chitnumsub P, et al. Preclinical evaluation of the antifolate QN254, 5-chloro-N¢6¢-(2,5- dimethoxy-benzyl)-quinazoline-2, 4,6- triamine, as an antimalarial drug candidate. Antimicrob Agents and Chem 2010;54:2603-10
32. Medicines for malaria venture. Antimalarial compounds with flexible side-chains. WO09048957; 2009
33. Sirawaraporn W, Sathitkul T, Sirawaraporn R, et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci 1997;94:1124-9 (Pubitemid 27087815)
34. University of Connecticut. Inhibitors of Dihydrofolate reductase with antibacterial, antiprotozoal, antifungal and anticancer properties. US20090105287; 2009
35. Pelphrey P, Popov V, Joska T, et al. Highly efficient ligands for DHFR from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J Med Chem 2007;50:940-50 (Pubitemid 46393997)
36. Dana-Farber Cancer Institute. Pharmaceutically active compounds and methods of use thereof. 7119095; 2006
37. Auspex Pharmaceuticals. Diaminoquinazoline inhibitors of dihydrofolate reductase. 20100150896; 2010
38. Dihydrofolate reductase inhibition by epigallocatechin gallate compounds. US20070249545; 2007
39. Chroma Therapeutics. Pyrimidine derivatives useful as DHFR inhibitors. WO07129020; 2007
40. Chroma Therapeutics. DHFR enzyme inhibitors. WO07132146; 2007
41. Dana-Farber Cancer Institute. Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same. US6989386; 2006
42. Novel inhibitors of folic acid-dependent enzymes. US20100249141; 2010
43. Inhibitors of folic acid-dependent enzymes. US7718660; 2010
44. Chelsea Therapeutics. New classical antifolates. US20080214585; 2008
45. Abraham A, McGuire J, Galivan J, et al. Folate analogs. 34. Synthesis and antitumor activity ofnon-polyglutamylatable inhibitors of dihydrofolate reductase. J Med Chem 1991;34:222-7
46. BTG International Ltd. Anti-cancer cyclopenta[g]quinazoline compounds. US7705006; 2010
47. Duquesne University of the Holy Spirit. Thieno pyrimidine compounds. US20090326224; 2009